Intellia Therapeutics Releases Earnings Results, Misses Expectations By $0.08 EPS | NTLA Message Board Posts


Intellia Therapeutics Inc.

  NTLA website

NTLA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  27 of 28  at  8/8/2023 4:53:45 PM  by

jerrykrause


Intellia Therapeutics Releases Earnings Results, Misses Expectations By $0.08 EPS

Pharma & Healthcare Monitor Worldwide
 
 

Intellia Therapeutics Releases Earnings Results, Misses Expectations By $0.08 EPS

 
 

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.08), Briefing.com reports. The firm had revenue of $13.59 million during the quarter, compared to the consensus estimate of $12.08 million. Intellia Therapeutics had a negative net margin of 804.94% and a negative return on equity of 41.67%. The firm's quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.33) earnings per share.

Intellia Therapeutics Trading Up 1.3 %

3 Biotech Stocks to Buy for Long-Term Gains

NTLA traded up $0.52 on Friday, hitting $39.61. 940,329 shares of the company's stock were exchanged, compared to its average volume of 1,051,483. Intellia Therapeutics has a fifty-two week low of $32.44 and a fifty-two week high of $69.73. The firm has a 50-day moving average price of $42.11 and a 200-day moving average price of $40.41. The stock has a market cap of $3.49 billion, a price-to-earnings ratio of -7.42 and a beta of 1.84.

Insiders Place Their Bets

In other Intellia Therapeutics news, EVP Eliana Clark sold 5,000 shares of Intellia Therapeutics stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $45.00, for a total transaction of $225,000.00. Following the sale, the executive vice president now owns 45,146 shares of the company's stock, valued at approximately $2,031,570. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Muna Bhanji sold 1,867 shares of the company's stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $39.30, for a total value of $73,373.10. Following the completion of the sale, the director now owns 12,526 shares of the company's stock, valued at $492,271.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eliana Clark sold 5,000 shares of the company's stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $45.00, for a total transaction of $225,000.00. Following the completion of the sale, the executive vice president now directly owns 45,146 shares of the company's stock, valued at approximately $2,031,570. The disclosure for this sale can be found here. Insiders have sold a total of 7,492 shares of company stock valued at $324,174 in the last 90 days. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

3 More Mid-Cap Biotechs The Street Sees Doubling

A number of hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in Intellia Therapeutics by 1.3% during the first quarter. JPMorgan Chase & Co. now owns 671,132 shares of the company's stock worth $25,014,000 after buying an additional 8,515 shares during the period. Rockefeller Capital Management L.P. boosted its stake in Intellia Therapeutics by 37.6% during the first quarter. Rockefeller Capital Management L.P. now owns 32,149 shares of the company's stock worth $1,198,000 after buying an additional 8,788 shares during the period. Merlin Capital LLC boosted its stake in Intellia Therapeutics by 2.5% during the first quarter. Merlin Capital LLC now owns 12,610 shares of the company's stock worth $470,000 after buying an additional 307 shares during the period. Squarepoint Ops LLC boosted its stake in Intellia Therapeutics by 200.9% during the first quarter. Squarepoint Ops LLC now owns 274,204 shares of the company's stock worth $10,220,000 after buying an additional 183,080 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its stake in Intellia Therapeutics by 28.1% during the first quarter. Steward Partners Investment Advisory LLC now owns 2,686 shares of the company's stock worth $100,000 after buying an additional 590 shares during the period. Hedge funds and other institutional investors own 88.47% of the company's stock.

Analyst Ratings Changes

A number of analysts recently commented on NTLA shares. Chardan Capital lowered their target price on shares of Intellia Therapeutics from $111.00 to $107.00 in a research note on Tuesday, June 13th. Bank of America raised their price target on shares of Intellia Therapeutics from $89.00 to $91.00 in a research report on Tuesday, June 13th. Canaccord Genuity Group began coverage on shares of Intellia Therapeutics in a research report on Thursday, April 13th. They set a "buy" rating and a $66.00 price target for the company. StockNews.com began coverage on shares of Intellia Therapeutics in a research report on Thursday, May 18th. They set a "sell" rating for the company. Finally, BMO Capital Markets raised their price target on shares of Intellia Therapeutics from $57.00 to $64.00 in a research report on Friday, May 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $82.06.

 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...